Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on Cardiovascular Events (DECLARE TIMI-58) trial, which he presented at the American Heart Association 2018 Scientific Sessions in Chicago.
DECLARE-TIMI 58 tested the hypotheses that dapagliflozin is safe and efficacious for the reduction in the occurrence of important cardiovascular events. DECLARE-TIMI 58 is the largest trial with an SGLT-2 inhibitor to address these questions in a broad population of patients with Type 2 diabetes mellitus, and includes participants both with established cardiovascular disease and those without cardiovascular disease, but with multiple cardiovascular risk factors.
Read the full DocWire News report on DECLARE-TIMI 58 here.
Read more coverage of the AHA 2018 Scientific Sessions here.